Angiotech completes Neucoll merger:
This article was originally published in Clinica
Executive Summary
Angiotech Pharmaceuticals has completed its acquisition of Neucoll, a privately-held orthobiologics company based in Los Gatos, California. Vancouver, Canada-based Angiotech first announced its intention to acquire all the share capital of Neucoll in July (see Clinica No 1114, p 13) as part of its strategy to build up its orthopaedics business. With this $13m all-cash transaction, Angiotech has bought Neucoll's two key products, the Collagraft and Neugraft bone graft matrixes.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.